Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.